Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2

• Main Authors: Haiyan Yan (Author), Jing Sun (Author), Kun Wang (Author), Huiqiang Wang (Author), Shuo Wu (Author), Linlin Bao (Author), Weiqing He (Author), Dong Wang (Author), Airu Zhu (Author), Tian Zhang (Author), Rongmei Gao (Author), Biao Dong (Author), Jianrui Li (Author), Lu Yang (Author), Ming Zhong (Author), Qi Lv (Author), Feifei Qin (Author), Zhen Zhuang (Author), Xiaofang Huang (Author), Xinyi Yang (Author), Yuhuan Li (Author), Yongsheng Che (Author), Jiandong Jiang (Author)
• Format: Book
• Published: Elsevier, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development. No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections. We report herein that a macrolide antibiotic, carrimycin, potently inhibited th...